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Abstract
T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive malignancy of thymocytes. Using
a transgenic screen in zebrafish, thymocyte selection-associated high mobility box protein (TOX)
was uncovered as a collaborating oncogenic driver that accelerated T-ALL onset by expanding the
initiating pool of transformed clones and elevating genomic instability. TOX is highly expressed in
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a majority of human T-ALL and is required for proliferation and continued xenograft growth in
mice. Using a wide array of functional analyses, we uncovered that TOX binds directly to
KU70/80 and suppresses recruitment of this complex to DNA breaks to inhibit Non-Homologous
End Joining repair (NHEJ). Impaired NHEJ is well known to cause genomic instability, including
development of T cell malignancies in Ku70 and Ku80 deficient mice. Collectively, our work has
uncovered important roles for TOX in regulating NHEJ by elevating genomic instability during
leukemia initiation and sustaining leukemic cell proliferation following transformation.

Introduction

Author Manuscript
Author Manuscript

T-cell acute lymphoblastic leukemia (T-ALL) affects thousands of children and adults each
year in the United States (1). There are many molecular subtypes of T-ALL, with those
expressing the master transcriptional regulators TAL1 and LMO1/LMO2 comprising 60% of
new diagnoses (2). Despite their wide differences in transcription factor activation and arrest
at different stages of T cell development (1,3), T-ALL subtypes also commonly rely on
similar oncogenic pathways for transformation. For example, MYC is now widely
recognized as the dominant oncogenic driver in human T-ALL and is often activated
downstream of NOTCH1 in a variety of T-ALL subtypes (4). Additional oncogenic drivers
also likely collaborate with these potent oncogenes to elevate proliferation, alter tumor
initiation, and expand early transformed T cell pools. For example, T-ALLs often harbor
genomic deletion of p16INK4A, focal amplification of cMYB, and aberrant activation of
TAL1 by genomic deletion of the SIL locus (1,2). Chromosomal translocations are also
common in T-ALL and often result in mis-expression of oncogenic transcription factors or
creation of novel oncogenic gene fusions that drive transformation and growth (2,5). Finally,
recent studies have uncovered novel mechanisms to deregulate oncogenes in T-ALL through
acquired small genomic insertions and deletions that drive high transcript expression and are
acquired through aberrant DNA repair (6,7). Despite the high number of genomic
aberrations found in human T-ALL and the supposition that these are driven by errant DNA
repair, it has yet to be fully established how these genetic lesions are acquired and what, if
any, DNA repair pathways may be altered in human T-ALL.

Author Manuscript

Non-homologous End Joining (NHEJ) is important for restoring genomic integrity to cells
and provides a rapid and robust mechanism to re-ligate broken DNA strands to protect cells
from undergoing apoptosis. Following the creation of a double-strand break (DSB), NHEJ
repair can be initiated by recruitment of dimeric KU70/KU80 to sites of DNA damage (8).
Other NHEJ factors are then recruited to the DNA lesion including DNA-dependent protein
kinase catalytic subunit (DNA-PKcs), Artemis, XRCC4, Ligase IV and XLF/Cernunnos (9).
These proteins facilitate repair by ligating the DNA ends and restoring DNA integrity. Not
unexpectedly, impaired NHEJ often results in DNA translocations, inversions, and deletions
that are characteristic of cancer (10). In fact, mice deficient in Ku70 or Ku80 have elevated
genomic instability and develop T cell malignancies (11,12). Yet, KU70/KU80 and other
NHEJ repair factors are not commonly deleted, mutationally inactivated, or hypermethylated in human T cell lymphoma or T-ALL, leading investigators to conclude that
these pathways may not be dominant oncogenic drivers of T-ALL nor have important roles
in regulating aberrant DNA changes seen at leukemia initiation. To date, mechanisms that
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regulate elevated genomic instability and/or alter NHEJ repair in human T-ALL have not
been established.

Author Manuscript

Using a transgenic screen in zebrafish, we have identified thymocyte selection-associated
high mobility group box protein (TOX) as a collaborating oncogene that synergized with
MYC and intracellular NOTCH1 to initiate early onset T-ALL, to expand the number of
transformed clones, and to elevate genomic instability. TOX contains a single HMG box
motif and has been suggested to be a transcription factor based solely by its homology with
other HMG containing proteins. Yet, TOX shares remarkable conservation in protein
sequence within its HMG box domain with well-known chromatin remodeling proteins that
lack DNA binding specificity. Importantly, TOX regulates various aspects of T cell
development (13–19) and is also genomically amplified in a subset of mouse and human TALL (20). Work presented here has uncovered that TOX is transcriptionally activated by
well-known T-ALL oncogenic transcription factors, including TAL1 and LMO1/2.
Functional studies revealed that TOX regulates both proliferation and NHEJ in human TALL and unexpectedly, these functions do not require binding of TOX to the chromatin.
Rather, the HMG box of TOX binds directly to and inhibits KU70/KU80, impairing its
recruitment to sites of DNA damage. Thus, one function of TOX is to lock human T-ALL
cells in a state of dampened NHEJ repair. In total, our results provide a plausible cellular
mechanism for elevated genomic DNA aberrations observed in human T-ALL and reveal
additional roles for TOX in regulating proliferation after leukemic cell transformation.

RESULTS
TOX accelerates onset and malignant transformation in zebrafish MYC-induced T-ALL

Author Manuscript
Author Manuscript

To identify genes that collaborate with MYC to accelerate time to T-ALL onset, we
completed a transgenic screen in zebrafish (Fig. 1a). Importantly, the zebrafish transgenic
MYC-induced T-ALL model provides a robust and powerful tool to assess oncogenic drivers
required to initiate T-ALL (21–24). This model shares remarkably similar molecular
mechanisms of transformation with those found in mouse and human (21,23–25). Moreover,
zebrafish T-ALL also harbor similar genomic DNA amplifications and deletions when
compared with both human and mouse T-ALL (26,27), supporting conserved roles for
genomic instability in driving T-ALL onset. In total, 27 genes were included in our screen
based on being highly expressed, amplified, and/or mutationally activated in human T-ALL
(Supplementary Table S1 and Supplementary Fig. S1a). Fish with fluorescent labeled
thymocytes were followed for disease progression after 21 days of life, with leukemia being
defined by >50% of the animal being overtaken by fluorescent-labeled T-ALL cells (24,26).
From this analysis, 8 genes were identified that significantly shortened time to leukemia
onset and increased disease penetrance (p<0.05, Log-rank statistic, Fig. 1b). As has been
previously found using mouse models of T-ALL, BMI1 (28), HIF1α (29), IL7R mutations
(30), and GFI1 (31) were identified as collaborating oncogenes in our screen, validating that
similar genes and pathways drive leukemogenesis in zebrafish, mouse, and human (Fig. 1b).
Our work also uncovered thymocyte selection-associated high mobility group box protein
(TOX) as a novel collaborating oncogene that synergized with both MYC and activated
intracellular NOTCH1 to induce T-ALL (Fig. 1b,c and Supplementary Fig. S1b).
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Importantly, TOX alone was insufficient to transform thymocytes over the 150 days of
observation.
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To define a role for TOX in modulating T-ALL initiation and growth, we next undertook a
cellular and molecular characterization of MYC and MYC+TOX expressing T-ALL. Both
MYC and MYC+TOX- expressing T-ALL arose exclusively within the thymus (Fig. 1c), had
similar lymphoblast morphology (Fig. 1f), and expressed T-cell markers, including higher
TOX expression in double transgenic animals (Fig. 1g). Zebrafish MYC and MYC+TOX
expressing T-ALLs expressed both tal1/scl and lmo2, confirming that TOX did not alter the
subtype of T-ALL induced in zebrafish (Fig. 1g). EdU labeling experiments showed that
proliferation rates also did not differ between MYC- or MYC+TOX-expressing T-ALL
(p=0.34, Student’s t-test, n>9 T-ALL assessed per genotype, Fig. 1d). However, TOXexpressing T-ALL had slightly fewer apoptotic cells when assessed by Annexin-V staining
(Fig. 1e, p=0.012, ANOVA test). Finally, clonal analysis uncovered that MYC+TOX
expressing T-ALLs had a dramatic 3-fold increase in TCRβ-recombined clones (MYC
+TOX, 7.4+/−1.5 clones compared to MYC, 2.4+/−0.3; p=0.0001, Mann Whitney test, Fig.
1h and Supplementary Table S2). We conclude that TOX has prominent roles in
transforming early thymic precursor cells and acts by expanding the overall pool of
transformed clones at leukemia initiation.
TOX induces genomic instability in zebrafish T-ALL and MEFs

Author Manuscript

Human T-ALLs often harbor genomic deletions and amplifications indicative of genome
instability and can be assessed clinically by quantitative changes in DNA content following
propidium iodide (PI) staining and flow cytometry (32). This same methodology has been
previously adapted to zebrafish T-ALL and is a rapid assay to identify leukemias with
genomic copy number changes (25). As previously reported, 17% of zebrafish MYCinduced T-ALL had increased DNA content (n=13 of 75) (25). By contrast, 47% of MYC
+TOX expressing T-ALLs had altered DNA content (n= 8 of 17, p=0.013, Fisher Exact test,
Fig. 2a,b). TOX expressing T-ALLs also comprised a substantial fraction of leukemias that
were hypodiploid, contrasting starkly with zebrafish MYC induced T-ALL where
hypodiploidy has never been observed (p=0.006, Fisher Exact test). Together, these results
show that TOX is a critical driver of genomic instability in zebrafish Myc-induced T-ALL.

Author Manuscript

To validate that TOX-expressing T-ALLs have elevated genomic instability and harbored
alterations in genomic DNA, low-pass whole genome sequencing (WGS) was completed
using Illumina Hiseq (0.5–1.0X genome coverage). Low-pass WGS can effectively detect
deletions and amplifications akin to array comparative genomic hybridization (array CGH).
When compared to matched control tissue isolated from the same leukemic fish, all three
MYC+TOX leukemias showed large-scale genomic variations including deletions, gains,
and amplifications (Fig. 2c,d and Supplementary Table S3). No recurrent lesions were
identified in all three of the TOX+MYC expressing T-ALLs (Supplementary Table S3),
indicating that TOX does collaborate with a specified set of amplifications or deletions to
drive transformation, but rather TOX is likely a general modulator of genomic instability.
Three Myc-induced T-ALLs were also analyzed by WGS, confirming DNA content changes
identified by FACs and overall less DNA copy number aberrations when compared with
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TOX expressing T-ALLs (Fig. 2d and Supplemental Table S3). Taken together, these results
independently confirm that TOX imparts elevated genomic instability to zebrafish T-ALL
cells.

Author Manuscript

To further assess a role for TOX in regulating genomic instability, TOX was transfected into
mouse embryonic fibroblasts (MEF) cells and chromosomal abnormalities were assessed by
metaphase spread (Fig. 2e,f). This analysis revealed that TOX significantly elevated genomic
instability that was indicative of impaired NHEJ including elevation in unrepaired
chromosome breaks and loss/gains of chromosome arms (p=0.005, Two Tailed Student’s ttest; Fig. 2f). MEF cells that expressed a mutant form of TOX that lacked the HMG box, as a
result of deletion of amino acids 261–339, also did not exhibit elevated genomic instability
when compared with control treated cells (p=0.15, Student’s t-test). These data further
support a role for TOX in elevating genomic instability and suggest prominent roles for the
HMG box domain in regulating this process.
TOX is expressed in a majority of human T-ALL and is regulated by the TAL1/MYB
transcriptional complex

Author Manuscript

To determine the extent of TOX expression in human T-ALL, we next analyzed transcript
expression in a wide array of human cancer cell lines and uncovered that TOX was highly
expressed in human T-ALL (Fig. 3a). This observation was extended to primary T-ALL
patient samples, showing that TOX transcripts were highly expressed in human primary TALL when compared to normal marrow, irrespective of molecular subtype classification
(n=157 of 165 primary T-ALL express high transcript levels of TOX, Fig. 3b and
Supplementary Fig. S2a,b). TOX protein expression was also assessed by Western blot
analysis and showed that TOX was expressed in both human T-ALL cell lines and primary
patient samples (n=10, Fig. 3c and Supplementary Fig. S2c,d). FACS analysis confirmed
high expression of TOX at single cell resolution in a large fraction of primary human TALLs (Fig. 3d,e). By contrast, TOX protein was detected at lower levels in human
thymocytes and B-ALL (n=5).

Author Manuscript

Given that TOX is highly expressed in a large fraction of human T-ALL and yet only
amplified in a small subset of human leukemias (20), we next investigated how TOX might
be transcriptionally regulated in malignant T cells. High levels of H3K27ac occupancy are
associated with recruitment of mediator and master transcription factors, which define
stretch/super enhancers that ultimately drive high transcript expression (33,34). Genomic
analysis uncovered elevated H3K27ac occupancy near the TOX locus in human T-ALLs but
not immature and mature T-cell subsets or CD34+ marrow cells (Fig. 3f). Super-enhancer
analysis revealed two prominent genomic regions that drive high transcript expression in
human T-ALL cells, but were not found in normal thymocytes or mature T cell subsets
(Supplementary Table S4). Further analysis of H3K27ac peaks revealed that super-enhancer
#2 contained both the mediator complex and master T-ALL transcription factors including
TAL1, MYB and GATA3 (Fig. 3g). Knockdown of these factors and additional members of
the TAL1 complex including HEB and E2A, led to significant reduction in TOX transcript
expression in human T-ALL cells (Fig. 3h). We conclude that high TOX transcription is
regulated, at least in part, by super-enhancer regulation in human T-ALL.
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To assess the consequences of TOX loss of function, HPB-ALL, CCRF-CEM, and MOLT-4
human T-ALL cells were transduced with shRNAs against TOX and compared with
scramble control shRNA. Following stable knockdown of TOX using independent shRNAs,
all three T-ALL cell lines had reduced viability and overall growth when assessed by Cell
Titer-Glo (Fig. 4a,b). EdU proliferation analysis showed that shTOX knockdown T-ALL
cells exhibited a marked disruption of cell cycle, with arrest of cells in S-phase and overall
reductions in cycling G2/M cells (Fig. 4c). TOX shRNA knockdown cells also had higher
levels of apoptosis when assessed by Annexin-V/PI staining when compared with control
cells (p<0.02, Student’s t-test, Fig. 4d and Supplementary Figure S3). These results show
that TOX has major roles in regulating human T-ALL cell growth and leukemia
maintenance, impacting both cell cycle and apoptosis.

Author Manuscript

To extend our findings to the in vivo setting, human HPB-ALL and CCRF-CEM knockdown
cells were transduced with luciferase and assessed for growth in NOD/Scid/IL2Rγ null
mice. TOX knockdown cells exhibited significantly reduced xenograft growth by 21 days
when compared with control shRNA treated cells (Fig. 4e–j). Together, these data show that
TOX also has important roles in regulating continued growth and maintenance of human TALL cells in vivo.
TOX binds directly with KU70/KU80 through the HMG box domain

Author Manuscript

To develop hypotheses about how TOX might be regulating transformation, we sought to
identify TOX binding partners. Specifically, endogenous TOX antibody pull-down
experiments were performed in human HPB-ALL, MOLT4, and Jurkat T-ALL cells and
interacting factors identified through liquid chromatography–mass spectrometry (LC-MS/
MS). Following separation of proteins on an SDS-page gel, prominent protein bands were
detected in the TOX pull down cell lysates from HPB-ALL cells but not the IgG control
cells (Supplementary Fig. S4). These bands were excised and analyzed by LC-MS/MS.
From this analysis, KU70 and KU80 were identified as TOX binding factors (Supplementary
Table S5a). Additional LC-MS/MS experiments performed in MOLT4 and Jurkat cells
confirmed the KU70/KU80 interaction with TOX using analysis of total protein eluates
obtained following endogenous TOX immunoprecipitation (Supplementary Table 5b). In
these experiments, KU70 and KU80 exhibited a remarkable >22-fold enrichment over IgG
control pull down cells, independently verifying TOX interaction with KU70/KU80.

Author Manuscript

To confirm Ku70/KU80 protein interactions identified by mass spectrometry, TOX
immunoprecipitation was performed in the presence and the absence of DNase I and
Western blot analysis completed with KU70 and KU80 specific antibodies in all three
human T-ALL cell lines. DNase I treatment ensured that interactions of TOX and KU70/
KU80 did not result from binding common genomic DNA fragments (Fig. 5a). As was seen
by the IP-mass spectrometry experiments, TOX interacted with KU70/KU80 in human HPBALL, CCRF-CEM and MOLT-4 human T-ALL cell lines (Fig. 5a and Supplementary Fig.
S5a). Reciprocal immunoprecipitation using the KU70 antibody confirmed specificity of the
interaction (Fig. 5a, right panel). Consistent with our LC-MS/MS experiments, Western blot
analysis also revealed that late acting NHEJ factors including XRCC4 and DNA Ligase IV
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did not pull down with TOX (Fig. 5b), showing that the interaction of TOX with KU70/
KU80 was limited to the dimeric initiating complex that is first recruited to DNA double
strand breaks (DSBs). In vitro binding assays using purified protein and performed in the
absence of DNA confirmed a direct interaction between TOX, KU70, and KU80 (Fig. 5d
and Supplementary Fig. S5b). By contrast, HMG deleted TOX was unable to bind KU70/
KU80 in in vitro binding assays (Fig. 5d), confirming a requirement for this domain in
regulating the TOX protein:protein interaction with dimeric KU70/KU80.

Author Manuscript

Endogenous antibody pull down and in vitro binding assays showed the HMG box motif
was responsible for protein:protein interactions with KU70 and KU80 and did not require
DNA binding; thus, we wondered if, like other HMG group box containing proteins, TOX
bound chromatin. Cell fractionation studies were performed in human HPB-ALL T-ALL
cells and identified that TOX was highly expressed in the nuclear fraction and to a lesser
degree to the cytoplasm; yet TOX did not bind to chromatin (Fig. 5c). Irradiation of cells
induces large amounts of DNA damage and facilitates recruitment of repair enzymes to
DNA breaks. Despite high dose irradiation of human T-ALL cells, TOX was still not
recruited to chromatin even after 60 minutes following 3Gy irradiation treatment (Fig. 5c
and Supplementary Fig. S5c). We conclude that TOX binds directly to KU70/KU80 through
its HMG box domain and that this protein:protein interaction does not require DNA binding.
TOX inhibits DNA repair by suppressing recruitment of NHEJ factors to DSBs

Author Manuscript
Author Manuscript

Given the prominent roles for KU70/KU80 in regulating NHEJ and subsequently genomic
instability (11,12) and that TOX over expression in zebrafish T-ALL and MEFs lead to
genomic instability, we hypothesized that TOX might be an inhibitor of KU70/KU80
function and thus affect NHEJ repair. Full-length TOX or deletion mutants that lack the NLS
or HMG box domain were stably expressed in 3T3 fibroblast cells (Fig. 5e and
Supplementary Fig. S6a). Cells were then transfected with linearized plasmid that contained
a DNA DSB between the promoter and the GFP coding sequence, where GFP is expressed
only following successful DNA repair. Cells expressing full-length TOX exhibited a
remarkable 54+/−4.5% reduction in DNA repair when compared with control cells (Two
tailed Student’s t-test, p=0.0004, +/− STD, Fig. 5e), while 3T3 cells expressing TOX
deletion mutants that lack the HMG box or nuclear localization domain did not have altered
NHEJ. Epistasis experiments revealed that when both KU70 and KU80 were expressed
together, NHEJ was fully restored to TOX expressing cells (Fig. 5f). By contrast, expression
of either KU70 or KU80 alone was not sufficient to restore NHEJ in TOX expressing cells
(Fig. 5f). Suppressed NHEJ was also observed in 3T3 cells transfected with red fluorescentprotein fusions of mRuby2 with full-length TOX but not when fused with deletion mutants
that lack the HMG box domain (Fig. 5g). Imaging studies verified that both full-length TOX
and HMG box deleted TOX were predominantly localized to the nucleus (Fig. 5g) while the
NLS mutant was localized to the cytoplasm (Supplementary Fig. 6b).
To directly assess if TOX modulates recruitment of KU70/KU80 to the sites of DNA repair,
3T3 fibroblasts were transfected with KU80-GFP and mRuby2, mRuby2-TOX or mRuby2ΔHMG, subjected to UV laser microirradiation-induced DNA damage, and assessed for
KU80-GFP recruitment to DSBs (Fig. 5h). Cells expressing full-length TOX exhibited
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significantly reduced recruitment of KU80-GFP to DNA breaks (p<0.05, Student’s t-test),
while cells that expressed mRuby2-ΔHMG efficiently recruited KU80-GFP to sites of DNA
damage with similar kinetics to control cells. mRuby2-TOX and fusions with HMG deleted
TOX were not recruited to microirradiation induced breaks and remained nuclear localized
throughout these experiments. Impaired recruitment of NHEJ pathway regulators to sites of
DNA damage was independently confirmed using XRCC4-GFP (p<0.05, Student’s t-test,
Fig. 5i). These experiments show that TOX sequesters KU70/KU80 away from sites of
active DNA repair.
TOX loss of function in human T-ALL leads to elevated NHEJ repair

Author Manuscript

We hypothesized that TOX might lock human T-ALL cells in a state of dampened DNA
repair, with the prediction that loss of TOX should elevate NHEJ repair. Stable knockdown
or shRNA expressing control cells were transfected with linearized plasmid that contained a
DNA DSB between the promoter and the mCherry coding sequence, with fluorescence only
being detected following successful DNA repair. Plasmid based repair assays showed that
HPB-ALL, CCRF-CEM, and MOLT4 T-ALL cells all exhibited enhanced NHEJ repair
following stable TOX knock down using independent shRNAs (Fig. 6a–f and Supplementary
Fig. S7; p<0.05, Student’s t-test). Similar results were obtained using stable integration of
the Traffic Light Reporter (TLR). The TLR assay reads out NHEJ repair via RFP expression
following induction of a DSB using tamoxifen-inducible I-SceI restriction enzyme (35).
These experiments showed that NHEJ repair was greatly increased following TOX
knockdown in CCRF-CEM cells, exhibiting a striking increase in NHEJ following TOXdepletion (p=0.0001, Two-tail Student’s t-test, Fig. 6g,h).
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To independently confirm a role for TOX in modulating DNA DSB repair, we next assessed
the kinetics and localization of 53BP1 and γH2A.X in irradiated CCRF-CEM and HPBALL T-ALL cells following stable knockdown of TOX. 53BP1 and γH2A.X are recruited to
DNA following induction of DSBs and their kinetics can be measured to quantify resolution
of the breaks following γ-irradiation (36). Using this strategy, we found that TOX
knockdown led to significantly faster DNA break resolution in human T-ALL cells following
3Gy irradiation (Fig. 6i,j; Supplementary Fig. S8; p<0.001, Student’s t-test). The overall
numbers of foci were also reduced at many early time points reflecting ongoing and faster
repair in TOX depleted cells following irradiation-induced DSB damage. Similar results
were also seen in irradiated HPB-ALL cells (Supplementary Fig. S8; p<0.001, Student’s ttest). Together, our data indicate that TOX negatively regulates the NHEJ pathway in human
T-ALL and that human T-ALLs are locked in a state of dampened DSB DNA repair
(Supplementary Fig. S9).

Author Manuscript

DISCUSSION
Our work has uncovered TOX as a novel collaborating oncogenic driver in T-ALL with
important roles in both leukemia initiation and maintenance. TOX is amplified in a small
subset of mouse and human T-ALL and was included in our screen based on these results
(20). Yet, our work uncovered that most human T-ALLs express high levels of TOX and that
this high transcript expression largely results from super enhancer regulation by well-known
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T-ALL transcription factors including TAL1 and LMO1/2. Thus, TOX does not commonly
meet the criteria for being a classically-defined oncogene which are activated by
translocation, amplification or activating mutations, but rather TOX is expressed in
developing T-ALL cells by oncogenic transcription factors, locking leukemia cells both in a
state of heightened proliferation and dampened DNA repair. Importantly, TOX also had
unexpected roles in regulating leukemia initiation by expanding the pool of initiating clones
and elevating genomic instability in the zebrafish T-ALL model. Experiments completed in
MEF cells confirmed roles for TOX in inducing genomic instability and generating
chromosomal aberrations. Finally, studies of human T-ALL and xenograft studies revealed
additional roles for TOX in regulating continued leukemia maintenance by specifically
regulating cell cycle proliferation and apoptosis. These results are in keeping with known
roles for TOX in regulating cell cycle in primary Sezary cells and Cutaneous T-cell
Lymphoma where TOX knockdown led to cell cycle arrest and secondarily cell death (37).
Collectively, our work has identified TOX as a new collaborating oncogenic driver in T-ALL
and which likely exerts important and diverse functional effects in a large fraction of human
T-ALLs.

Author Manuscript

Because TOX had been previously shown to regulate proliferation in primary Sezary cells
and Cutaneous T-cell Lymphoma (37), our studies focused on uncovering additional roles
for TOX in regulating DNA repair pathways. Remarkably, our endogenous TOX pull-downs
and subsequent LC-MS mass spectrometry analysis uncovered potent interactions between
TOX and KU70/KU80, prompting further investigation into roles for TOX in regulating
DNA repair and NHEJ. Loss of NHEJ repair genes in mice are well-known to cause elevated
genomic instability and cancer. For example, KU70 and KU80 deficiency in mice results in
genomic instability and predisposition to T cell malignancy (11,12). Yet, genetic loss of
KU70 or KU80 or disruption of other NHEJ factors has not been implicated as a major
tumor suppressor pathway in human T-ALL. Rather our work has shown that TOX acts as a
negative regulator of KU70/KU80 function to alter NHEJ repair and to elevate genomic
instability. Remarkably, TOX remains highly expressed in fully malignant human T-ALL
and locks leukemia cells in a state of dampened NHEJ repair, an observation confirmed
using a wide array of DNA repair assays performed directly in human T-ALL cells. Even
more remarkable is that TOX performs this function by directly binding KU70/KU80 and
does not require binding to chromatinized DNA. Perturbations in NHEJ result in the creation
of deletions, amplifications, transversions, and translocations that impart growth advantages
to early transformed cells and drives cancer initiation. Thus, it is not surprising that
mutations in DNA repair proteins can alter NHEJ and are predisposing to cancer. Our work
strongly suggests that TOX may be such a factor in T-ALL.

Author Manuscript

Our results also suggest the existence of a new class of HMG group box proteins that
function without binding chromatinized DNA. Indeed, endogenous chromatin
immunoprecipitation studies and DNA-free in vitro binding assays show that TOX does not
bind to chromatin. Rather, the HMG box domain of TOX is required for protein:protein
associations with KU70/KU80 and functionally impairs recruitment of NHEJ factors to
breaks. TOX contains a single highly conserved HMG box motif that is structurally distinct
from both class I and II HMG box group containing proteins (38). Class I HMG box group
proteins are transcription factors and contain a single HMG box that binds DNA in a
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sequence-specific manner. These transcription factors include the TCF/LEF1 and SOX
family members and have important roles in regulating a wide array of developmental and
cancer processes (39). By contrast, class II group proteins contain two DNA-binding motifs,
bind chromatin in a sequence agnostic manner, and have important roles in modifying DNA
structure. For example, HMGB1 modulates nucleosome structure and alters transcription by
looping chromatinized DNA to facilitate interaction of transcription factors with enhancer
elements (40). HMGB1 also regulates a multitude of DNA repair pathways (41–43). For
example, HMGB1 can enhance in vitro DNA ligase activity, by bringing DNA ends into
close proximity (44). Yet, to date, functional roles for HMGB1 and other class II HMG
group box proteins in regulating DNA bending and repair necessarily require binding to
chromatin.

Author Manuscript

Together, our data suggest that TOX may represent the first of a novel class of HMG
proteins that function, at least in part, by binding regulatory proteins through their HMG box
and regulating NHEJ repair. Given the prominent role TOX has in T cell development and its
coordinated regulation coincident with TCRβ and TCRα rearrangement in mice, it is also
possible that TOX may have roles in development including regulation RecombinationActivating Gene (RAG)-mediated recombination. Moreover, TOX is highly and specifically
expressed in human T cell malignancies while its related family members TOX2, TOX3, and
TOX4 are differentially regulated in a variety of human cancers including Breast cancer,
Ewing sarcoma, Multiple Myeloma and Small Cell Lung cancer (45–47). Many of these
tumors are well known to have elevated genomic instability and harbor characteristic lesions
that are associated with impaired NHEJ. It will be important to assess whether these closely
related TOX family members share molecular functions in regulating cell proliferation,
transformation and genomic instability in a wider range of human cancers.

Author Manuscript

Materials and Methods
Transgenic DNA expression constructs

Author Manuscript

DNA constructs used to generate transgenic zebrafish included rag2:mCherry (23),
rag2:MYC (21) and rag2:NICD (24). All genes, except FNBP1, GFI1, GITR, BMI1 and
TOX, used in this screen were obtained from hORFeome (48). IL7R constructs were created
using site-directed mutagenesis. Full-length ORFs for human FNBP1, GFI1 and GITR were
obtained by PCR-amplification of cDNA derived from human T-ALL cells. Zebrafish TOX
was amplified from the cDNA of 1 to 5-day-old Tu/AB zebrafish and subcloned into pENTR
gateway system (Life Technologies). PCR primer sequences can be found in Table S6. All
genes were transferred into the rag2 promoter destination vector using LR clonase II (Life
Technologies).
Creation of zebrafish T-ALL
Plasmids were linearized with NotI or XhoI and purified. Mosaic transgenic animals were
generated as previously described (22). 40 ng/μL rag2:mCherry was mixed with 40 ng/μL of
rag2:Myc or rag2:NICD and 40 ng/μL rag2:experimental gene and micro-injected into onecell stage Tu/AB embryos. Animals were scored for fluorescent-labeled thymi at 21 and 28
days of life and then followed weekly for disease onset. Leukemic fish are defined by >50%
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of their body being infiltrated with fluorescent T-ALL cells as previously described (24,26).
Zebrafish experiments were approved under animal protocol 2011N000127 (MGH).
Clonality, proliferation, apoptosis and DNA content

Author Manuscript

Proliferation was assessed using the Click-IT EdU kit (Life Technologies) according to the
manufacturer protocol. A pulse of EdU was performed following cell harvest and completed
for 1h at 28.5°C. Zebrafish T-ALL cells were assessed for apoptosis using DAPI and Alexa
Fluor 647-conjugated AnnexinV (Life Technologies). Numbers indicate the mean of ≥9
biological replicates +/− the s.e.m. For DNA content, 1×106 zebrafish T-ALL cells were
permeabilized in 70% ice-cold Ethanol for >2hrs at −20°C. Cells were then incubated in
500μL of a solution containing 50μg/mL PI, 1mg/mL PureLink RNase and PBS-1% BSA
for 30 minutes at 25°C. EdU-stained cells, AnnexinV-stained cells and DNA content were
then analyzed using LSR II or Fortessa Flow Cytometer (BD Biosciences). The DNA index
quantifies differences in total DNA in the test cell population in relation to that in normal
diploid cells, comparing maximal G0/G1 peak heights between samples when assessed by
FACs. A DNA index of 1.0 is indicative of normal diploid cells.
The zebrafish TCRB recombination assay was first described by Blackburn et al. (24).
Briefly, RNA was extracted from FACS-sorted T-ALL cells, made into complementary
DNA, and PCR was performed utilizing each Vb and Cb primer (51 variable spanning PCR
primers and 2 constant regions). A semi-nested PCR was completed using 1 μl of the PCR
product and resolved on a 2% agarose gel. From this analysis, we can quantify the overall
numbers of clones contained within the leukemia (24,26).

Author Manuscript

RT-qPCR was performed on bulk leukemias (n=5 fish/genotype) and compared with FACs
sorted rag2:GFP+ thymocytes (n=2 samples). Samples were run in triplicate, with error bars
representing the s.e.m of compiled data from all replicates and experimental samples.
Genomic DNA sequencing of zebrafish T-ALL

Author Manuscript

Zebrafish genomic DNA was extracted from T-ALL cells using a solution containing 10mM
Tris-EDTA, 0.2% SDS, 200mM NaCl and 200μg/mL Proteinase K following incubation at
50°C for >16hrs. The next day, the Proteinase K was heat-inactivated at 95°C for 10min.
The gDNA extract was then purified using genomic DNA clean and concentrator (Zymo).
Purified zebrafish gDNA was sheared and made into a library by the MGH Next generation
sequencing core. Next-generation sequencing of zebrafish gDNA from MYC, MYC+TOX
and WT samples was performed using Illumina HiSeq Instrument. Following alignment to
the Zv9 genome using BWA (49), analysis of large-scale genomic variants using HMMCopy
(50). In addition, a direct comparison of mutant and WT coverage was performed by
calculating read coverage within non-overlapping 10 Kb windows across the genome. The
log-log scatter plots of the resulting read counts from leukemias were compared to the
corresponding WT tissue isolated from the same fish.
Metaphase spread on mouse MEF cells
MEF cells were transfected with control, full-length TOX, and dHMG box containing TOX.
After 48h post transfection, MEF cells were incubated with 100ng/μL KaryoMax Colcemid
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for 90min (Life Technologies), washed and incubated for 18 min with 0.075M KCl. 1mL of
a 3:1 Methanol:glacial acetic acid (fixative solution) was added to the chromosome
preparation and centrifuged 10min at 400g, 4°C. The pellet was washed 2 times with 3mL of
fixative solution and resuspended in 1mL of fixative solution. Chromosomes were spread on
microscope slides and dried 10min at room temperature. DAPI Fluoromount-G (Southern
Biotech) was added to each slide and imaged. At least 50 nuclei are counted per condition
and per experiment. Experiments were replicated 3 independent times.
Gene expression analysis of TOX in human T-ALL

Author Manuscript

TOX transcript expression was assessed in human cell lines using the Cancer Cell Line
Encyclopedia (45) (GSE36139) and in human T-ALL patient samples using the program R2:
Genomics Analysis and Visualization Platform (http://r2.amc.nl). Data sets included
normalized gene expression for healthy bone marrow (GSE13159) and human leukemia
samples comprising the “Mixed Leukemia – MILE – 2004” (GSE13159) and “Tumor ALL
(T) - Meijerink – 124” datasets (GSE26713). Statistical analysis and visualization was
completed using Prism6.0. Whiskers plots have been utilized to visualize the data and are
represented using the Tukey method. Primary human samples used in this work were
collected under the IRB DFCI 05-001.
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Protein lysates were extracted using RIPA buffer, quantified using Coomassie Plus Bradford
protein assay (Pierce), and analyzed by Western blot analysis. Specifically, denaturated
proteins were loaded on a 4–20% gradient gel (Biorad) and then transferred to a PVDF
membrane (Biorad). Antibody staining was visualized using Amersham ECL Prime reagent
(GE Healthcare) followed by analysis using a Fluor-S MultiImager (Biorad). Band intensity
was quantified using the ImageJ software package. Human T-ALL cells were assessed by
Western blot analysis using primary antibodies for α-TOX (1:1000 dilution, eBioscience),
α-GAPDH (1:2500, #2118, Cell Signaling Technology), α-TAL1 (1:200, BTL73, EMD
Millipore), α-LMO2 (1:200, sc-65736, Santa Cruz Biotechnology) and α-cleaved NOTCH1
(1:1000, #4147, Cell Signaling Technology). The secondary antibodies used were HRPconjugated anti-rat IgG (1:2000, #7077, Cell Signaling Biotechnology), HRP-conjugated
anti-rabbit IgG (1:2500, #7074, Cell Signaling Biotechnology) and HRP-conjugated antimouse IgG (1:5000, G21040, Life Technologies).
Mouse xenografts and luciferase imaging
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Human T-ALL cells were luciferized using the pLKO.1-luc-mKate (gift from Drs.
Matthijssens and Van Vlierberghe, Ghent University, Belgium) and equal numbers of viable
cells were injected into the flanks of six-week-old NOD/SCID/IL2rg null female mice
(1×106 of viable cells per 200 μl). Mice were anesthetized by isofluorane and leukemia
growth was monitored by bioluminescence imaging following subcutaneous injection into
the loose tissue over the neck of 75mg/kg D-luciferin (Perkin Elmer) in 100 μl of PBS.
Comparisons of leukemia size used an ANOVA test and Student’s T-test comparisons
between control and treated cells. Mouse experiments were approved under animal protocol
2013N000038 (MGH).
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Reads were aligned to the hg19 version of the human genome using bowtie (51) with
parameters –k2 –m 2 –best –sam and –l set to read length. Wiggle files to display the density
of reads relative to genomic loci were created with MACS (52) with parameters –w –S –
space=50 –nomodel –shiftsize=200 –keep-dup=1. The wiggle files were subsequently
normalized to the millions of unique positions covered by reads. Wiggle files were displayed
in the UCSC genome browser. Array file name used in this study are indicated in Table S6.
Super-enhancer identification
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Super-enhancers were identified in two stages as described previously (34,53). First,
constituent enhancers were defined as peaks of H3K27ac using MACS with two sets of
parameters to account for focal amplifications: -p 1e-9–keep-dup=1 and –p 1e-9 –keepdup=all. Second, the union of these sets of peaks was used as input for ROSE, which stitches
proximal enhancer constituents and ranks stitched enhancers by signal. ROSE was run with
parameters –s 12500 and –t 1000 to stitch constituents within 12.5kb of each other and
exclude constituents fully contained within +/−1kb from promoters of RefSeq genes.
Stitched enhancers were each assigned to the single expressed RefSeq gene locus whose
transcription start site is most proximal to the center of the stitched enhancer. Genes were
considered expressed if they were in the top 2/3 of all TSS when ranking by promoter
H3K27ac density. RPM-normalized promoter H3K27ac density was calculated in 1kb
windows center on TSSs using bamToGFF with parameters –e 200 –m 1 –r –d.
Immunoprecipitation and Western blot analysis
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Immunoprecipitation was performed using 300μg of protein lysate along with 4μg of TOX
antibody (GeneTex), KU70 antibody (ab3108, Abcam) or control rabbit IgG (Santa Cruz
Biotechnology). Immunoprecipitation was completed in the presence of 30–40μL of
Dynabeads Protein G (Life Technologies) and incubated for 16h at 4°C in Cell Lysis Buffer
(Cell Signaling Technology). Beads were then washed 5 times and proteins were eluted
using denaturating Laemmli, at 95°C for 10min. Denaturated proteins were loaded on a 4–
20% gradient gel (Biorad) for Western Blot analysis and then transferred to a PVDF
membrane (Biorad). Antibody staining was visualized using Amersham ECL Prime reagent
(GE Healthcare) followed by analysis using a Fluor-S MultiImager (Biorad). Band intensity
was quantified by ImageJ. For DNase I treatment, EDTA- free lysis buffer was used to
prepare cell lysates. MgCl2 was added to the final concentration of 0.4 mM. 2.5 μl of 5
mg/ml DNase I were added to 500 μg of cell lysates. The digestion was performed by
rotating at room temperature for 10 minutes. EDTA was then added to the final
concentration of 5 mM to stop the nuclease reaction.
Primary antibodies were α-TOX (1:1000 dilution, eBioscience), α-KU70 (1:1000, ab92450,
Abcam), α-KU80 (1:1000, #2753, Cell Signaling Technology), α-GAPDH (1:2500, #2118,
Cell Signaling Technology), α-XRCC4 (1:200, sc-365118, Santa Cruz Biotechnology), and
α-LIGASE IV (1:200, sc-271299, Santa Cruz Biotechnology). The secondary antibodies
used were the same as described above.
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TOX and ΔHMG were subcloned into pT7CFE1-NHis-GST-CHA plasmid using the BamHI
and XhoI restriction enzyme sites. 4μg of each construct was then transcribed and translated
using the 1-Step Human High-Yield mini IVT kit (Pierce). TOX proteins were purified using
the MagneGST Protein Purification System (Promega) and interactions with KU70/KU80
assessed on column. Specifically, 0.5μg–3μg of KU70/KU80 proteins (Abcam) were added
to TOX bound beads. Following 2 hours of binding at 25°C, samples were washed 5-times
using wash binding buffer supplied from the manufacturer (Pierce). TOX was cleaved from
the beads using HRV3C protease (Pierce), purified away from beads, and the elution loaded
on a 4–20% gradient gel for Western blot analysis. In vitro binding assays were performed
three independent times.
Cell lines and Authentication
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NIH3T3 and MEF cells were obtained from ATCC in 2012 and 2015, respectively and used
within three months of receipt. Human T-ALL cell lines, MOLT-4, CCRF-CEM, HPB-ALL,
JURKAT, DND-41, KE-37, KOPTK1, MOLT13, P12-ICHIKAWA, PEER were a gift from
A. Thomas Look in 2012. Human HEK293T cells were ordered from ATCC in 2012. All
human cell lines were authenticated at receipt and just prior to use in experiments using
Small Tandem Repeat profiling and certified mycoplasma (MycoAlert Plus, Lonza, tested
every 6 months).
Cell fractionation
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Cell fractionation was completed essentially as described by the manufacturer (Subcellular
Protein Fractionation kit, Pierce; 1×107 human T-ALL cells). However, one additional wash
was utilized in each cell fraction. Protein fractions were quantified by Bradford assay and
20μg–45μg of proteins were loaded on a 4–20% gradient gel for Western blot analysis.
Primary antibodies were α-TOX, α-TUBULIN (1:500, ab4074, Abcam), α-SP1 (1:1000,
#9389, Cell Signaling Technology), and α-H4 (1:1000, #2935, Cell Signaling Technology).
The secondary antibodies used were the same as described previously. Cell fractionation was
performed three times with similar results.
Transient assays for NHEJ in 3T3 cells and human T-ALL cells

Author Manuscript

For the NHEJ assay, DNA double strand break was made in pEGFP-N1 vector or a pCS2GW-mCherry by double-digestion with XhoI/BamHI and EcoRI/BamHI respectively,
similarly to previous published work (54). When 3T3 cells were 70% confluent, they were
transfected with control or TOX expressing vectors with or without KU70 and/or KU80.
Cells were also transfected at the same time with linearized NHEJ reporter DNA into a 6well plate (TransIT-X2 reagent, Mirus Bio). For nucleofection experiments in human T-ALL
cells, 5×105 cells were nucleofected with control or TOX expressing vectors along with
linearized NHEJ reporter DNA. The Amaxa Cell Line Nucleofector kit L was used for HPBALL and CCRF-CEM, while kit V was used for MOLT-4 (program A-030, Lonza). 48hrs/
72hrs post transfection/nucleofections, the cells were analyzed by flow cytometry counting
the number of GFP or mCherry positive cells and normalized to the number of fluorescent
reporter cells. These assays were performed three independent times in triplicate.
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Live cell imaging following micro-irradiation induced DNA damage
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Human TOX or the HMG box deletion mutant were gateway-cloned into the pDest26
expression vector (Life Technologies). mRuby was then subcloned in frame using SalI and
BglII. pmRuby2, pmRuby2-TOX or pmRuby2-ΔHMG constructs were co-transfected into
3T3 cells with KU80-GFP or XRCC4-GFP using electroporation (Neon transfection system,
Life Technologies). 8–24 h later, cells were treated with Hoescht 33342 and subjected to 405
nm laser-induced micro-irradiation and imaging as described previously (55). Images were
processed and analyzed using Slidebook 5.0 software (Intelligent Imaging Innovations) and
Adobe Photoshop CS6. Quantification of fluorescence intensity was measured within laser
track regions and normalized to regions outside the track for each time point (> 15 cells
assessed for each time point).
Lentivirus infection and Traffic Light Reporter assay
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Sequences for each shRNA are provided in Supplementary Table 6. 2μg of pLKO-shTOX or
pLKO-scramble (Addgene plasmid 1864) were cotransfected into HEK 293T cells with 2μg
pCMV-dR8.91, 0.2μg pVSV-g and TransIT-LT1 reagent (Mirus Bio). Supernatants
containing the lentivirus were collected, filtered, and added to T-ALL cell lines in the
presence of 4μg/mL polybrene (Millipore). T-ALL cells were spinoculated at 2000g for
90min at 32°C. 2 days post-infection, cells were selected by adding 6μg/mL puromycin
(Invivogen). For the Traffic Light reporter assay, 2μg pCVL-TLR-Ef1a-BFP (Addgene
plasmid 31481) (35) was cotransfected in addition to the previous plasmids. BFP positive
cells were FACs sorted on the Aria Flow Cytometer (BD Biosciences). BFP positive,
puromycin-selected cells were then nucleofected with tamoxifen-inducible I-SceI expressing
vector (gift from Dr. Mostoslavsky, MGH). 24h post nucleofection, 200nM of Tamoxifen
was added to the cells and incubated for 48h before FACs analysis. These experiments were
repeated in triplicate and repeated twice.
Tandem mass spectrometry (LC-MS/MS)
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Gel separated samples were alkylated with iodoacetamide and digested overnight at pH 8.3
with sequencing grade trypsin (Promega). Peptide mixtures were analyzed by microcapillary
liquid chromatography-tandem mass spectrometry (LC-MS/MS) using the EASY-nLC
nanoflow HPLC (Thermo Fisher Scientific) with a 75μm inner diameter × 15 cm length C18
capillary column coupled to a hybrid Orbitrap Elite mass spectrometer (Thermo Fisher
Scientific). The Elite was operated in data-dependent acquisition (DDA) mode (1 profile FTMS spectrum followed by 15 centroided IT-MS/MS spectra). The resolution was 60,000 in
FT-MS mode and MS/MS spectra were read out at low resolution via CID in the Velos ion
trap. The gradient consisted of 3–38% acetonitrile in 0.1% formic acid (FA) at a flow rate of
300 nL/min for 75 min, 38–95% acetonitrile in 0.1% FA for 2 min and held at 95%
acetonitrile in 0.1% FA at for 7 min followed by column re-equilibration for 10 min at 3%
acetonitrile in 0.1% FA. MS/MS fragmentation spectra were searched for protein
identification using the Mascot search engine against the reversed and concatenated
SwissProt protein database (v7_2012).
Carbamidomethylation of Cys was set as fixed modification and variable modifications were
oxidation of Met and deamidation of Gln and Asn. Precursor ion mass tolerance was set to
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12 ppm and fragment ion mass tolerance was set to 0.8 Da. Two missed cleavages were
allowed and the minimal length required for a peptide was six amino acids. Relative
quantification of proteins was achieved through peptide spectral counting using Scaffold 4
software. The peptide and protein false discovery rates (FDR) were set to 1.5%.
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To confirm the results from identifying proteins from selected protein bands from SDSPAGE gels, the unfractionated sample of affinity enriched proteins was reduced and
alkylated in solution basically as described previously (56). Proteins then were precipitated
with chloroform-methanol, resuspended in 4 M urea/50 mM HEPES (pH 8.5) and digested
using first endoproteinase LysC (Wako) and then sequencing grade trypsin (Promega). The
generated peptides were analyzed by LC-MS2 in a 70 min gradient on an Orbitrap Fusion
mass spectrometer equipped with an EASY-nLC 1000 autosampler/HPLC pump. The mass
spectrometer was operated in a data-dependent mode with a full MS spectrum acquired in
the Orbitrap followed by MS2 spectra acquired in the linear ion trap on the most abundant
ions detected in the full MS spectrum. MS2 spectra were assigned using a SEQUEST-based
(57) proteomics analysis platform (58) by searching against the human Uniprot sequence
database. Peptide and protein assignments were filtered to a false discovery rate of < 1 %
employing the target-decoy database search strategy (59) and using linear discriminant
analysis and posterior error histogram sorting. Peptides with sequences contained in more
than one protein sequence from the database were assigned to the protein with most
matching peptides (58). Interacting proteins were assigned by the following criteria: 1) at
least 10 independent peptides must be found in the TOX pull down samples and 2) there
must be at least a 3 fold enrichment over IgG-pull down controls.

Supplementary Material
Author Manuscript

Refer to Web version on PubMed Central for supplementary material.
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Statement of Significance
TOX is a HMG box containing protein that has important roles in T-ALL initiation and
maintenance. TOX inhibits the recruitment of KU70/KU80 to DNA breaks thereby
inhibiting non-homologous end joining repair. Thus, TOX is likely a dominant oncogenic
driver in a large fraction of human T-ALL and enhances genomic instability.

Author Manuscript
Author Manuscript
Author Manuscript
Cancer Discov. Author manuscript; available in PMC 2018 November 01.

Lobbardi et al.

Page 21

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Figure 1. TOX collaborates with MYC to accelerate T-ALL onset

(a) Schematic of transgenic screen. (b) Kaplan-Meier analysis (p<0.05, Log-Rank Statistic).
Leukemic fish have >50% of their body overtaken by T-ALL cells. Number of animals
analyzed per genotype is shown in parenthesis. (c) Images of T-ALL transgenic fish at 21,
28 and 35 days post-fertilization (dpf). Asterisks denote auto-fluorescence. Arrowheads
show leukemias initiating in the thymus. Scale bar equals 2mm. (d) EdU proliferation
analysis of zebrafish T-ALL. Not significant (NS). +/− STD noted. (e) Annexin-V apoptosis
staining as assessed by flow cytometry. Asterisk denotes p<0.05, Two-tailed Student’s t-test.
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+/− STD noted. ≥9 primary T-ALLs were analyzed per genotype in d,e. (f) Cytospin
showing lymphoblast morphology (n>5 leukemias/genotype analyzed). Scale bar is 20μm.
(g) RT-qPCR gene expression comparing MYC and MYC+TOX expressing T-ALL (n=5 per
genotype, run in triplicate) with sorted thymocytes isolated from rag2:GFP transgenic fish
(purity >95%, viability >95%). *: p<0.05; ***: p<0.001, Two-tailed Student’s t-test. Not
significant (NS). Error bars denote standard error of the mean. (h) Number of TCRβ clones
per primary leukemia (MYC+TOX: n=9 animals; MYC: n=24 animals). Asterisk indicates
p<0.05, Two-tailed Student’s t-test. Error bars denote standard error of the mean.
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Figure 2. TOX promotes genomic instability

(a) Flow cytometry analysis showing DNA content of zebrafish T-ALL (blue) compared to
normal blood-derived DNA (red). Representative leukemias are shown with changes in DNA
index noted (DI). 2n has a DNA index of 1. (b) Quantization of DNA content. Asterisk
denotes p=0.013, Fisher Exact Test. (c) Genomic DNA alterations identified by whole
genome sequencing. The log-log scatter plot represents read counts within non-overlapping
window size of 10 kb across the genome comparing leukemia and control tissue from the
same, representative animal. Amplifications found in the MYC+TOX leukemia are denoted
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by the green circle. (d) Manhattan plot representing the copy number variation across the
genome of a representative MYC (top) and MYC+TOX (bottom) expressing T-ALL.
Regions of significant gain, amplification (AMPL), high level amplification (HLAMPL),
and neutral 2N copy number (NEUT) noted. (e-f) Analysis of metaphase spreads from MEF
cells infected with control (MOCK), full-length Wild-type TOX (TOX WT), or TOX that
lacks the HMG box domain (TOX dHMG). Arrows denote chromosome abnormalities. (f)
Quantification of cells with genomic abnormalities. >50 nuclei were counted per condition
and replicated three independent times. Error bars denote standard deviation. *, p<0.05 and
**, p<0.005, Student’s t-test. Not significant (NS).
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Figure 3. TOX is highly expressed in human T-ALL and transcriptionally regulated in a subset
of leukemias by the TAL1/MYB complex

(a) TOX microarray gene expression from the Cancer Cell Line Encyclopedia. Box-andwhisker plots denote median TOX expression (black line), the inter-quartile range (box) and
1.5× the inter-quartile range (bars). (b) Volcano plot comparing gene expression between
human T-ALL patient samples and bone marrow. (c) Western blot analysis of primary
human leukemia (top) and T-ALL cell lines (bottom). The same thymus sample was run in
lane 1, top and lane 2, bottom. (d) Flow cytometry analysis showing TOX expression in
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primary human T-ALL compared with B-ALL. Control is T-ALL cells stained with
conjugated IgG control antibody (ctr). (e) Quantification showing the percentage of TOX+
cells found in each patient sample (right panel, **, p=0.006, Two-tailed Student’s t-test).
Mean and standard error of the mean are denoted. (f-h) TOX is associated with two distinct,
H3K27 acetylated super-enhancers (SE) in human T-ALL. (f) ChIP sequencing of human T
cells, CD34+ progenitor cells from the marrow (black peaks), and T-ALL cell lines (red
peaks). Super-enhancer 1 (SE 1) is found in MOLT-3 and Jurkat, while SE 2 is found in all
three human T-ALL cell lines. (g) Magnified view of SE 2 in Jurkat T-ALL cells showing
super-enhancer occupancy by the TAL1/MYB complex. (h) TOX gene expression in Jurkat
cells following knockdown of T-ALL transcription factors found within the H3K27
acetylated super-enhancer (***, p<0.001; **, p<0.01; *, p<0.05, data set from GSE29179;
+/− standard error of the mean denoted).\
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Figure 4. TOX is required for continued human T-ALL growth and maintenance

(a) Western blot analysis following stable shRNA knockdown in human T-ALL cells.
Percent knockdown noted. (b) Cell viability following knockdown as assessed by Cell
TiterGlo. (c) EdU proliferation analysis. (d) Annexin-V staining. Asterisks in b-d denote
p<0.05, Student’s t-test. Xenograft studies performed with human HPB-ALL (e-g) and
CCRF-CEM (h-j). (e,h) Flow cytometry analysis showing efficiency of TOX knockdown.
(f,i) Luciferase bioluminescent imaging of representative animals engrafted at 0 days
compared with 21 days. Scramble shRNA control (left flank) or shRNA-TOX #2 (right
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flank). (g,j) Quantification of xenograft growth using two independent shRNAs. Not
significant (NS), p<0.05 (*), p<0.01 (**), and p<0.001 (***), ANOVA test.
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Figure 5. TOX binds directly to the KU70/KU80 and inhibits Non-Homologous End Joining by
suppressing recruitment of KU70/KU80 to sites of DNA damage

(a) TOX immunoprecipitation followed by Western blot analysis in HPB-ALL cells in the
presence or absence of DNAseI treatment. The right panel shows the reciprocal
immunoprecipitation using anti-KU70. (b) TOX immunoprecipitation followed by Western
blot analysis for members of the NHEJ pathway. (c) Western blot analysis following cell
fractionation in non-irradiated and 3Gy-irradiated HPB-ALL cells. TUBULIN, SP1 and
Histone H4 (H4) are controls for assessing cytoplasmic, nucleoplasmic and chromatin
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fractions, respectively. (d) In vitro binding of TOX (WT) or HMG-box (ΔHMG) deletion
mutant with KU70/KU80 followed by Western blot analysis. Negative control was KU70/
KU80 added to beads and then purified in the absence of TOX (Neg. Ctr). Loading control
contains only purified KU70/KU80 proteins (Load Ctr). (e) Western Blot analysis of 3T3
cells following transfection with full-length TOX (+), ΔHMG (ΔH), or ΔNLS (ΔN). Below is
the quantification of the NHEJ assay (NS: Not significant; ***, p<0.0001, Two-tailed
Student’s t-test comparing experimental samples with control, +/− STD noted). (f) Western
Blot analysis of 3T3 cells following transfection with full-length TOX, KU70 and/or KU80.
Below is shown the quantification of the NHEJ assay (**, p<0.001, ***, p<0.0001, Twotailed Student’s t-test, +/− STD noted). (g) Confocal imaging of 3T3 cells transfected with
mRuby2-fused constructs. Dashed lines denote nucleus as assessed by Hoechst stain (n>100
cells/construct analyzed). The lower right panel shows the fluorescence-based NHEJ assay
completed in 3T3 (*, p=0.03, Two-tailed Student’s t-test). +/− STD noted. (h,i) Quantitative
assessment of recruitment of KU80-GFP (h) or XRCC4-GFP (i) to sites of UV laser-induced
DNA damage in 3T3 cells. Asterisks denote significant differences (p<0.05, Two-tailed
Student’s t-test). +/− STD noted. Representative fluorescent images of cells following laserinduced damage are shown to the right.
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Figure 6. TOX loss-of-function increases DNA repair and accelerates the time to break resolution
in human T-ALL cells

(a–f) Transient repair assays in HPB-ALL (a–c) and CCRF-CEM (d–f) cells that have
shRNA knockdown. (a,d) Western blot analysis with percent knockdown noted. (b,e) Flow
cytometry analysis of knockdown and control cells following transient fluorescence-based
NHEJ assay. (c,f) Graphical summary of data. *, p<0.05; ***, p<0.001 when compared with
control shRNA treated cells, Two-tailed Student’s t-test. (g) Western blot analysis of TOX
expression in CCRF-CEM cells with stable TOX shRNA #2 or scramble control shRNA
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knockdown used in the Traffic Light Reporter assay. (h) Flow cytometry analysis of CCRFCEM cells stably integrated with the Traffic Light Reporter. Cells were nucleofected with
Tamoxifen-inducible I-SceI meganuclease and induced as noted in the figure. Percent of
cells that undergo NHEJ repair and express mCherry are noted (+/−1STD). ***, p=0.0001,
Two-tailed Student’s t-test. (i,j) Kinetics of the DNA repair in CCRF-CEM control and
stable knockdown down T-ALL cells (TOX shRNA #2). The number of 53BP1 (i) and
γH2A.X (j) foci per nucleus following 3Gγ irradiation are denoted. Each point represents
data from a single cell and the black bars denote the median foci per cell (***, p<0.0001,
Two-tailed Student’s t-test, >150 cells counted/condition). Box-and-whisker plots denote
expression with the median 75% of samples and bars 90%.
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